Target and Genmab Show Strength as S&P 500 Falls
Target and Danish biotech Genmab are among five stocks showing relative strength against the S&P 500 after a record weekly point loss. Target raised its earnings outlook, while Genmab reported positive cancer trial results. Cheesecake Factory, Netskope and Welltower also made the list.

Target and biotech company Genmab are among five stocks showing relative strength against the S&P 500 after the index’s worst weekly point loss on record. The group spans retail, restaurants, cybersecurity, cancer drugs and senior housing.
Target shares rose 2.7% for the week to 165.83 after the retailer raised its full-year earnings forecast. Genmab shares fell 1.5% to 50.60, following a 60% surge in October.
Target raises its earnings forecast
Target reported 49% growth in third-quarter earnings per share on 7% revenue growth. It raised its full-year earnings-per-share forecast to $10.65–$11.40 from $9.90–$10.90.
Truist analysts said nearly 60% of Target’s 5.6% comparable-store sales growth came from its Fun 101 category. The category includes revamped Fan Shops, which have helped drive trading card sales.
Truist cautioned that demand for collectibles can be fickle. The analysts said Target’s turnaround under new CEO Michael Fiddelke needs to broaden into apparel and home goods.
Cheesecake Factory shares ended the week down 1.1% at 107.95, despite a 7.2% jump during the week. The restaurant chain’s stock has moved largely sideways since October 27, while the S&P 500 has fallen 10%.
Comparable-store sales at its core Cheesecake Factory restaurants rose 15.2%. Traffic increased 9.5%, while the average ticket rose 5.7%, reflecting ordering choices and a 2.4% price increase.
William Blair analyst Sharon Zackfia highlighted menu changes, loyalty programs and “encouraging traction with younger guests.” She also pointed to increased alcohol consumption and sales of lower-priced Bites menu items.
Genmab reports cancer trial progress
Genmab’s October gains followed three positive developments in cancer treatment studies. Its Epkinly drug beat standard treatment in patients with a form of lymphoma, while Rina-S succeeded in a final-phase ovarian cancer study.
Genmab said a regimen using its drug petosemtamab cut the risk of death by 50% for patients with head-and-neck cancer. The stock reached a record high of 59.97 on October 28.
Netskope attracted two analyst price-target increases amid attention to artificial intelligence security threats. Rosenblatt raised its target to 28 from 19, while TD Cowen raised its target to 25 from 19.
Netskope shares rose 12.7% in one session during the week, then pulled back 3.5% in the final session. The cybersecurity company reports third-quarter results after the market closes on December 2.
Welltower reported 25% growth in normalized funds from operations, a measure of real estate operating performance, on 38% revenue growth in the third quarter. Rent increases accounted for 5.3% of the growth.
On its October 27 earnings call, Welltower said it had entered $21 billion in investments for the year, closing $13.3 billion through the third quarter.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Markets · FintechHow to Calculate Compound Interest: Formula, Examples and the Rule of 72
Lifestyle · Food & HealthNormal Blood Pressure Chart by Age: Healthy Ranges Explained
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say















